This site is intended for healthcare professionals. If you are a patient or caregiver, please contact your physician to discuss clinical trial eligibility.

Additional Clinical Trials

For more information email clinicaltrials@loxooncology.com.

Selective estrogen receptor degrader (SERD)


NCT04188548 open_in_new

A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

The reason for this study is to see if the study drug LY3484356 alone or in combination with abemaciclib is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

See Trial Information and Study Locations

CD73


NCT04148937 open_in_new

A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.

See Trial Information and Study Locations

CDK7


NCT03770494 open_in_new

A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors

The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer.

See Trial Information and Study Locations

ERK 1/2


NCT02857270 open_in_new

A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

See Trial Information and Study Locations

Aur A Kinase


NCT03898791 open_in_new

Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

See Trial Information and Study Locations
NCT04106219 open_in_new

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

See Trial Information and Study Locations

For additional information about these clinical trials, please refer to clinicaltrials.gov.

Interested physicians and patients may contact us at clinicaltrials@loxooncology.com.

Policy for Access to Investigational Agents

Loxo Oncology is committed to helping patients who have not responded to available therapies and may benefit from its investigational therapies. Loxo Oncology's Policy for Access to Investigational Agents describes the principles and government regulations that the company will follow when considering a request.

globe

For more information email clinicaltrials@loxooncology.com